John van Wye, MD
Allergy & Immunology · Asheville, NCNPI 1790776235
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,299 of the $11,115 with a category attached, or 65.7%. 29 manufacturers reported payments, led by Novartis at 35.7% of the total. Reporting peaked in 2024 at $5,377 and has fallen 78.8% since, to $1,140 in 2025.
Across 356 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- GSK$1K
- AstraZeneca$914
- CSL Behring$760
- Sanofi$668
- Regeneron Healthcare Solutions, Inc.$628
- plus $3K from 23 others
What the payments were for
- Consulting fees$3,75434%
- Food & beverage$7,29966%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $3,964 |
| GSK | 81 | $1,339 |
| AstraZeneca | 42 | $914 |
| CSL Behring | 30 | $760 |
| Sanofi | 34 | $668 |
| Regeneron Healthcare Solutions, Inc. | 23 | $628 |
| Amgen | 10 | $401 |
| Genentech USA, Inc. | 19 | $358 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $330 |
| Biocryst US Sales Co., LLC | 12 | $251 |
| Grifols USA, LLC | 13 | $242 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $235 |
| Pfizer | 8 | $155 |
| Alk-abello, Inc | 8 | $140 |
| Optinose US, Inc. | 7 | $121 |
| Kaleo, Inc. | 8 | $119 |
| Pharming Healthcare, Inc. | 7 | $104 |
| Hospira, Inc. | 4 | $88 |
| Boehringer Ingelheim | 4 | $70 |
| Merck | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Biocryst Pharmaceuticals, Inc. | 1 | $22 |
| USWM, LLC | 1 | $20 |
| AbbVie | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $18 |
| ADMA Biomanufacturing LLC | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,115 in reported general payments places this provider in the 65th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 24 | $73,100 |
| Dupixent PenDupilumab | 14 | $53,807 |
| Dupixent SyringeDupilumab | 11 | $38,898 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $32,522 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $20,605 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,706 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,287 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,946 |
| Epinephrine | 20 | $3,632 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $2,971 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $2,438 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,004 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $1,933 |
| Fluticasone Propionate | 64 | $1,182 |
| Montelukast Sodium | 119 | $1,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,339 | $53,12768 claims |
| AstraZenecaSymbicort | $914 | $6,70617 claims |
| Boehringer IngelheimSpiriva Respimat | $70 | $6,28712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Asheville
- William McCannAsheville$486K
- David BrownAsheville$129K
- Christopher CopenhaverAsheville$88K
- David CypcarAsheville$40K
- Elise CoulsonAsheville$16K
- Jordan SmallwoodAsheville$13K
- Catherine CranfordAsheville$7K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.